A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men

Healthy Clinical Trial

Official title:

A Two-Part, Open-Label, Fixed-Sequence, Two-Period Crossover Study to Assess the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone After Administration of the Relugolix/Estradiol/Norethindrone Acetate Fixed-Dose Combination Tablet in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix After Administration of a Single 120-mg Dose in Healthy Adult Men

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04714554
• Other study ID #: MVT-601-054
• Status: Completed
• Phase: Phase 1
• Start date: January 6, 2021
• Est. completion date: March 29, 2021

Study information

• Verified date: August 2021
• Source: Myovant Sciences GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a two-part, open-label, fixed-sequence, two-period crossover drug interaction study to assess the potential effects of erythromycin on the pharmacokinetics of relugolix, estradiol (E2), and norethindrone (NET) in healthy postmenopausal women (Part 1) and the pharmacokinetics of relugolix in healthy adult men (Part 2).

Description:

Each study part consists of two sequential treatment periods (Treatment Period 1 and Treatment Period 2) in which study participants will receive study treatments in a fixed (single)-sequence, crossover manner. In Part 1 of the study, a single relugolix/E2/norethindrone acetate (NETA) (40 milligrams [mg]/1 mg/0.5 mg) fixed-dose combination (FDC) tablet will be administered alone on Day 1 of Treatment Period 1; in Treatment Period 2, erythromycin will be administered on Day 1 to Day 12 (500 mg, four times daily [QID]) with co-administration of a single FDC tablet with the morning dose of erythromycin on Day 8. In Part 2 of the study, a single 120-mg dose of relugolix will be administered alone on Day 1 of Treatment Period 1; in Treatment Period 2, erythromycin will be administered on Day 1 to Day 12 (500 mg QID) with co-administration of a single 120-mg dose of relugolix with the morning dose of erythromycin on Day 8. There will be a nine-day washout interval between administration of study drug (the FDC tablet [Part 1] or relugolix 120 mg [Part 2]) on Day 1 of Treatment Period 1 and Treatment Period 2.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: March 29, 2021
• Est. primary completion date: March 29, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Key Inclusion Criteria:

• Study participant is considered to be medically healthy, based on a clinical evaluation including medical history, physical examinations, clinical laboratory tests, vital sign measurements, and a 12-lead electrocardiogram performed at the screening visit. Specifically, study participants should meet the following requirements at the screening visit:

• Heart/pulse rate of 50 to 90 beats per minute, inclusive;

• Systolic blood pressure of 90 to 139 millimeters of mercury (mmHg) and a diastolic blood pressure of 60 to 89 mmHg, inclusive;

• A QT interval with Fridericia's correction (QTcF, QTcF = QT/RR(0.33)) = 470 milliseconds;

• Normal renal function at the screening visit, defined as an estimated creatinine clearance = 90 milliliters (mL)/minute by the Cockcroft-Gault equation;

• An alanine aminotransferase, aspartate aminotransferase or bilirubin value within normal limits.

• Part 1 only: Study participant is a female between 40 and 65 years of age, inclusive, at the screening visit.

• Part 2 only: Study participant is a male between 18 and 65 years of age, inclusive, at the screening visit.

• Study participant has a body mass index from = 18.5 to = 32.0 (Part 1) or from = 18.5 to = 30.0 (Part 2) (kilograms/square meter), at the screening visit.

• Part 1 only: Study participant is a postmenopausal female defined as 12 months of spontaneous amenorrhea without an alternative medical cause or six weeks status post bilateral oophorectomy (with or without hysterectomy). A serum follicle-stimulating hormone (FSH) = 40 milli-international units/mL is required to confirm postmenopausal status. Note: women who are amenorrheic due to a surgical procedure (hysterectomy without oophorectomy) and are considered physiologically postmenopausal based on FSH values may participate.

Key Exclusion Criteria:

• Study participant has a clinically significant medical or psychiatric condition or disease (acute or chronic) that, as judged by the investigator, would make the study participant ineligible for participation in the study (for example, compromise the study data, limit the study participant's ability to complete and/or participate in the study).

• Study participant has a current condition or history of significant endocrine, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, urologic, immunologic, or neurologic disorders that, as judged by the investigator, would make the study participant ineligible for participation in the study.

• Study participants with a pre-existing condition interfering with normal gastrointestinal anatomy (with the exception of an uncomplicated appendectomy) or motility, hepatic and/or renal function that could interfere with the absorption, metabolism, and/or excretion of the study drugs.

• Study participant has unconjugated bilirubin values consistent with Gilbert's syndrome or a history of or current gall bladder or bile-duct disease.

• Part 1 only: Study participant has any contraindications to treatment with E2 and NETA, based on medical history:

• Undiagnosed abnormal genital bleeding;

• Known or suspected history of breast cancer;

• Known or suspected estrogen-dependent neoplasia;

• Active deep vein thrombosis, pulmonary embolism, or history of these conditions;

• Active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions;

• Known anaphylactic reaction or angioedema or hypersensitivity to estradiol or norethindrone acetate;

• Known hepatic impairment or disease;

• Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders.

• Study participant has used prescription or non-prescription drugs, including vitamins and dietary or herbal supplements within 14 days (or 5 half-lives, whichever is longer) prior to study drug administration on Day 1 of Treatment Period 1, unless in the opinion of the Sponsor the medication will not interfere with interpretation of study data or compromise the safety of study participants.

• Study participant has used any medication known to be a strong cytochrome P450 3A inducer and/or P glycoprotein inducer within the timeframe prior to study drug administration on Day 1 of Treatment Period 1.

• Part 1 only: Study participant has used medications containing hormonal products, including injectables, within the timeframe prior to study drug administration on Day 1 of Treatment Period 1.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Relugolix/E2/NETA FDC
Relugolix/E2/NETA (40 mg/1 mg/0.5 mg) FDC tablet; oral administration.
• Relugolix
Relugolix 120-mg tablets; oral administration.
• Erythromycin
Erythromycin 500-mg tablets; oral administration.

Locations

Country	Name	City	State
United States	Clinical Pharmacology of Miami, An Evolution Research Group Portfolio Company	Hialeah	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Myovant Sciences GmbH

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area Under The Concentration-time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Relugolix Or Other Analytes		Day 8 predose and up to 120 hours postdose at multiple time points during Treatment Period 2 (Study Days 10 to 22)
Primary	Maximum Plasma Concentration (Cmax) Of Relugolix Or Other Analytes		Day 8 predose and up to 120 hours postdose at multiple time points during Treatment Period 2 (Study Days 10 to 22)
Secondary	Overall Incidence Of Adverse Events		10 Weeks
Secondary	Predose Trough Plasma Concentrations (Ctrough) Of Erythromycin		Predose on Day 7 and 8 of Treatment Period 2 (Study Days 10 to 22)